Smad7 Antibodies

Santa Cruz Biotechnology features a diverse variety of Smad7 monoclonal antibodies for research in understanding cellular signaling pathways. Smad7 Antibodies are validated for western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). Smad7 is a critical regulator of the TGF-beta signaling pathway, acting as an antagonist to prevent excessive signaling that can lead to fibrosis and other pathological conditions. By modulating the activity of Smad proteins, Smad7 plays a vital role in maintaining cellular homeostasis and influencing processes such as cell proliferation, differentiation, and apoptosis. Understanding Smad7 function is essential for elucidating its implications in various diseases, including cancer and autoimmune disorders. Smad7 research has revealed significant roles in tissue repair, immune response regulation, and embryonic development. Investigating Smad7 expression patterns helps researchers understand its involvement in normal physiological processes and disease states. Current studies focus on how Smad7 regulation might be targeted for therapeutic interventions. Santa Cruz Biotechnology monoclonal antibodies support researchers worldwide in advancing scientific understanding of Smad7's role in health and disease.